The Defender, March 19, 2025: Operation Stork Speed will require increased testing for heavy metals and other contaminants in infant formula and will review nutrients. NCHR points out that a new Consumer Reports investigation found arsenic, lead, and PFAS in several types of infant formula, which confirms that this effort is long overdue.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
ADHD Drugs Under Scrutiny by RFK Jr.’s Make America Healthy Again (MAHA) Commission
Everydayhealth.com, March 17, 2025: President Trump’s executive order will create a MAHA Commission to examine the use of ADHD and psychiatric drugs for children. This news article focuses on whether access to ADHD drugs will harm children. NCHR reassures parents that access is unlikely to be harmed. We view the Commission as a good idea, but those views were not included in the article.
Read More »As Trump Administration Probes Long-Approved Medications, Could FDA Revoke Approvals?
Medscape March 6, 2025: MAHA Commission will study psychiatric, ADHD, and weight loss drugs’ impact on children. NCHR’s Diana Zuckerman agrees we need better evidence that the benefits of these drugs outweigh the risks.
Read More »Pfizer hires FDA drug regulator Cavazzoni, sparking revolving door debate
Politico, February 24, 2025: FDA Director of Drug Center (CDER), Cavazzoni, returns to Pfizer, where she worked before going to the FDA. NCHR and other experts say this revolving door undermines trust in the FDA and highlights concerns about the cozy relationship between the FDA and industry that can weaken standards of safety and effectiveness.
Read More »The Deadly Secrets Behind “Breakthrough” Alzheimer’s Drugs
The Lever, January 28, 2025: We are working with a consortium of experts to expose problems with FDA approvals. Our first article published in The Lever focuses on the clear risks and questionable benefits of drugs for early cognitive impairment caused by Alzheimer’s and how conflicts of interest resulted in approval.
Read More »